Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TTPA | P49638 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4078940 | 0.83 | MEN1 (0.35) | MEN1KMT2ACYP2C9ALOX15CYP2C19 | |
| SCHEMBL2417145 | 0.79 | MEN1 (0.44) | MEN1KMT2ACYP2C9ALOX15CYP2C19 | |
| SCHEMBL8957386 | 0.75 | MEN1 (0.70) | MEN1KMT2ACYP2C9ALOX15CYP2C19 | |
| SCHEMBL3304062 | 0.75 | BCHE (0.36) | MEN1KMT2ACYP2C9ALOX15CYP2C19 | |
| SCHEMBL2417322 | 0.75 | MEN1 (0.41) | MEN1KMT2ACYP2C9ALOX15CYP2C19 | |
| SCHEMBL9497805 | 0.75 | KMT2A (0.42) | MEN1KMT2ACYP2C9ALOX15CYP2C19 | |
| SCHEMBL9497895 | 0.75 | CYP2C19 (0.44) | MEN1KMT2ACYP2C9ALOX15CYP2C19 | |
| SCHEMBL2802998 | 0.75 | MEN1 (0.41) | MEN1KMT2ACYP2C9ALOX15CYP2C19 | |
| Fumaric Acid SCHEMBL9795102 | 0.74 | MEN1 (0.38) | MEN1KMT2ACYP2C9ALOX15CYP2C19 | |
| SCHEMBL8259935 | 0.74 | ALDH1A1 (0.42) | MEN1KMT2ACYP2C9ALOX15CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0641768-B1 | NITROXYALKYLAMIDE DERIVATIVE | SANKYO CO (JP) | 1997-07-23 | — | — | EP | claimed |
| EP-0641768-A1 | NITROXYALKYLAMIDE DERIVATIVE | SANKYO COMPANY LIMITED (JP) | 1995-03-08 | — | — | EP | claimed |
| EP-3901156-A1 | NITROOXYDERIVATIVE OF ROCK KINASE INHIBITOR | Vivavision (Shanghai) Ltd (CN) | 2021-10-27 | — | — | EP | disclosed |
| US-10968206-B2 | Cannabinergic nitrate esters and related analogs | NORTHEASTERN UNIVERSITY (US) | 2021-04-06 | — | — | US | disclosed |
| US-20190225596-A1 | Cannabinergic Nitrate Esters And Related Analogs | NORTHEASTERN UNIVERSITY | 2019-07-25 | — | — | US | disclosed |
| US-9580400-B2 | Cannabinergic nitrate esters and related analogs | NORTHEASTERN UNIVERSITY (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160002195-A1 | CANNABINERGIC NITRATE ESTERS AND RELATED ANALOGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-07 | — | — | US | disclosed |
| US-8703800-B2 | Nitrate and diazeniumdiolate derivatives of pioglitazone | CARDIOLYNX AG (CH) | 2014-04-22 | — | — | US | disclosed |
| EP-2576545-A1 | NITRATE AND DIAZENIUMDIOLATE DERIVATIVES OF PIOGLITAZONE | Cardiolynx AG (CH) | 2013-04-10 | — | — | EP | disclosed |
| US-20130072525-A1 | NITRATE AND DIAZENIUMDIOLATE DERIVATIVES OF PIOGLITAZONE | CARDIOLYNX AG (CH) | 2013-03-21 | — | — | US | disclosed |
| WO-2011151362-A1 | NITRATE AND DIAZENIUMDIOLATE DERIVATIVES OF PIOGLITAZONE | CARDIOLYNX AG (CH) | 2011-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002195-A1 | CANNABINERGIC NITRATE ESTERS AND RELATED ANALOGS | CNR2, CNR1, CHRNB3 | MEN1 3997/4885KMT2A 4178/4885CYP2C9 276/4885 |
| US-20130072525-A1 | NITRATE AND DIAZENIUMDIOLATE DERIVATIVES OF PIOGLITAZONE | PPARD, NOS2, PPARA | MEN1 4198/4885KMT2A 4142/4885CYP2C9 320/4885 |
| US-10968206-B2 | Cannabinergic nitrate esters and related analogs | CNR2, CNR1, CHRNB3 | MEN1 3997/4885KMT2A 4178/4885CYP2C9 276/4885 |
| US-20190225596-A1 | Cannabinergic Nitrate Esters And Related Analogs | CNR2, CNR1, CHRNB3 | MEN1 3997/4885KMT2A 4178/4885CYP2C9 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.